-
Ixazomib (trade name Ninlaro) is a drug for the
treatment of
multiple myeloma, a type of
white blood cell cancer, in
combination with
other drugs. It is...
- ciclesonide. On November, the U.S. Food and Drug
Administration approved Ixazomib developed by
Takeda for use in
combination with
lenalidomide and dexamethasone...
- for the
treatment of cancer.
Drugs such as bortezomib, carfilzomib, and
ixazomib are
already approved for use in
treating multiple myeloma and
mantle cell...
- pomalidomide), and a
proteasome inhibitor (e.g., or bortezomib,
carfilzomib or
ixazomib), in
combination with a
steroid (e.g., dexamethasone).
While triplet therapies...
-
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide)
IMPDI (Tiazofurin§) LI (Masoprocol) PARP
inhibitor (Fuzuloparib...
-
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide)
IMPDI (Tiazofurin§) LI (Masoprocol) PARP
inhibitor (Fuzuloparib...
- VELCADE". FDA.
Retrieved 2008-03-05. "U.S. FDA
Approves Takeda's NINLARO® (
ixazomib), the
First and Only Oral
Proteasome Inhibitor to
Treat Multiple Myeloma"...
-
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide)
IMPDI (Tiazofurin§) LI (Masoprocol) PARP
inhibitor (Fuzuloparib...
-
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide)
IMPDI (Tiazofurin§) LI (Masoprocol) PARP
inhibitor (Fuzuloparib...
-
Alitretinoin L01XF03
Bexarotene L01XG01
Bortezomib L01XG02
Carfilzomib L01XG03
Ixazomib L01XH01
Vorinostat L01XH02
Romidepsin L01XH03
Panobinostat L01XH04 Belinostat...
